---
title: "Zhitong A-share lock-up release overview | December 20"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/222865824.md"
description: "On December 20th, 10 listed companies will have their restricted shares unlocked, with a total market value of approximately 10.615 billion yuan. The unlocking situation includes JYC 66.1376 million shares, SUNYES 3.4655 million shares, Boteng Co., Ltd. 90,800 shares, HIRON COLD CHAIN 64,200 shares, RAYNEN 199,500 shares, Gan & Lee 1.234 million shares, Yonghe Co., Ltd. 1.6303 million shares, Zhiyou Technology 19.8465 million shares, Anbang Guardian 1.85484 million shares, and Hemai Co., Ltd. 4.1422 million shares"
datetime: "2024-12-20T01:01:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/222865824.md)
  - [en](https://longbridge.com/en/news/222865824.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/222865824.md)
generator: "portal-rs"
---

# Zhitong A-share lock-up release overview | December 20

According to the Zhitong Finance APP, on December 20th, a total of 10 listed companies will have their restricted shares unlocked, with a total market value of approximately 10.615 billion yuan.

The specific situation of the restricted share unlock today is as follows:

| Stock Abbreviation | Stock Code | Restricted Share Type                            | Number of Unlocked Shares |
| ------------------ | ---------- | ------------------------------------------------ | ------------------------- |
| JYC                | 000546     | Issuance of A-shares for legal person allocation | 6.61376 million           |
| SUNYES             | 002388     | Equity incentive restricted circulation          | 346,550                   |
| Boteng Co., Ltd.   | 300363     | Equity incentive restricted circulation          | 90,800                    |
| HIRON COLD CHAIN   | 603187     | Equity incentive restricted circulation          | 64,200                    |
| RAYNEN             | 603933     | Equity incentive restricted circulation          | 199,500                   |
| Gan & Lee          | 603087     | Equity incentive restricted circulation          | 1,234,000                 |
| Yonghe Co., Ltd.   | 605020     | Equity incentive restricted circulation          | 1,630,300                 |
| Zhiyou Technology  | 301376     | Extended restricted lock-up period circulation   | 19.8465 million           |
| Anbang Guardian    | 603373     | Pre-issuance share restricted circulation        | 18.5484 million           |
| Hemai Co., Ltd.    | 688032     |                                                  | 41.422 million            |

### Related Stocks

- [603933.CN](https://longbridge.com/en/quote/603933.CN.md)
- [603187.CN](https://longbridge.com/en/quote/603187.CN.md)
- [002388.CN](https://longbridge.com/en/quote/002388.CN.md)
- [000546.CN](https://longbridge.com/en/quote/000546.CN.md)
- [603087.CN](https://longbridge.com/en/quote/603087.CN.md)
- [301376.CN](https://longbridge.com/en/quote/301376.CN.md)
- [000001.CN](https://longbridge.com/en/quote/000001.CN.md)
- [300363.CN](https://longbridge.com/en/quote/300363.CN.md)
- [688032.CN](https://longbridge.com/en/quote/688032.CN.md)
- [603373.CN](https://longbridge.com/en/quote/603373.CN.md)
- [605020.CN](https://longbridge.com/en/quote/605020.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [Negative Link Announces Global Expansion and Next Phase of Growth](https://longbridge.com/en/news/296644416.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [06:00 ETCorelDRAW 2026 Review: New Features and Workflow Updates for Designers and Print Professionals Highlighted by Expert Consumers](https://longbridge.com/en/news/296698759.md)
- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**